Doctors Improve Diagnostic Test Interpretation Skills

Cystatin C is gaining attention as a kidney function marker for hospitalized patients, especially when traditional creatinine measurements may be unreliable.

Case highlights the diagnostic challenge

A 68‑year‑old man receiving chronic steroids for amiodarone‑induced thyroiditis was admitted with pneumonia, low blood pressure, and encephalopathy. Although antibiotics cleared the lung infection, his mental status continued to decline. The care team noted that serum creatinine remained within normal limits despite worsening neurologic function, prompting a search for a more sensitive renal marker.

In this context, the patient’s cystatin C level was measured and found to be markedly raised. The rise suggested a reduction in glomerular filtration that was not reflected by creatinine. Adjustments to medication dosing were made based on the cystatin C result, and the patient’s encephalopathy gradually improved as fluid balance and blood pressure were optimized.

Why cystatin C may be preferable in acute settings

Unlike creatinine, cystatin C is produced at a constant rate by all nucleated cells and is less affected by muscle mass, diet, or steroid use. Its serum concentration correlates closely with measured glomerular filtration rate, and it rises earlier in the course of acute kidney injury. For patients on steroids or with altered muscle bulk, cystatin C can therefore reveal declines in kidney function that creatinine misses.

The test is also less influenced by hepatic dysfunction, making it useful for patients with concurrent liver disease—a common scenario in inpatient medicine. However, cystatin C levels can be affected by thyroid disorders and inflammation, which clinicians must consider when interpreting results.

In the presented case, the raised cystatin C prompted a reassessment of fluid management and avoidance of further nephrotoxic exposures, which likely contributed to the patient’s neurologic recovery.

Comparing this situation to earlier reliance on creatinine alone, the shift mirrors past transitions in cardiac biomarkers where troponin replaced less specific enzymes, leading to earlier detection and better outcomes. Both examples illustrate how adopting more precise laboratory tools can refine clinical decision‑making.

Practical takeaways for clinicians

When encountering a hospitalized patient with unexplained encephalopathy, especially if they are on steroids or have altered muscle mass, measuring cystatin C can uncover hidden renal impairment. It should be considered alongside creatinine, rather than as a wholesale replacement, to provide a fuller picture of kidney health.

Clinicians should also be aware of factors that can falsely raise cystatin C, such as hyperthyroidism and systemic inflammation, and interpret results in the broader clinical context. Integrating cystatin C into existing protocols may require education and adjustments to electronic order sets, but the potential benefits in patient safety can justify the effort.

Overall, the case shows that cystatin C offers a valuable supplement to traditional kidney function tests, particularly in complex inpatient scenarios where accurate assessment is critical for therapeutic decisions.